Processa Pharmaceuticals Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
PCSA
- Investments
-
3
- Share Price
-
$1.82
- (As of Friday Closing)
Processa Pharmaceuticals General Information
Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Contact Information
Website
www.processapharmaceuticals.comCorporate Office
- 601 21st Street
- Suite 300
- Vero Beach, FL 32960
- United States
Corporate Office
- 601 21st Street
- Suite 300
- Vero Beach, FL 32960
- United States
Processa Pharmaceuticals Timeline
Processa Pharmaceuticals Stock Performance
As of 13-Nov-2026, Processa Pharmaceuticals’s stock price is $1.82. Its current market cap is $5.2M with 2.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.82 | $1.84 | $1.04 - $8.88 | $5.2M | 2.8M | 79.9K | -$4.33 |
Processa Pharmaceuticals Financials Summary
As of 30-Jun-2026, Processa Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,624 | 217 | 93 | 1,552 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (13,536) | (13,672) | (12,050) | (11,457) |
| Net Income | (13,438) | (13,564) | (11,850) | (11,122) |
| Total Assets | 2,070 | 7,814 | 3,229 | 5,787 |
| Total Debt | 0 | 0 | 74 | 151 |
Processa Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Processa Pharmaceuticals Comparisons
Industry
Financing
Details
Processa Pharmaceuticals Competitors (52)
One of Processa Pharmaceuticals’s 52 competitors is Vanda Pharmaceuticals, a Formerly VC-backed company based in Washington, DC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals | Formerly VC-backed | Washington, DC | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Novavax | Corporation | Gaithersburg, MD | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Processa Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Processa Pharmaceuticals Patents
Processa Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024297828-A1 | Methods of personalizing cancer treatment | Pending | 13-Jul-2023 | ||
| EP-4743092-A1 | Methods of personalizing cancer treatment | Pending | 13-Jul-2023 | ||
| US-20250017931-A1 | Methods of personalizing cancer treatment | Pending | 13-Jul-2023 | ||
| WO-2025015267-A1 | Methods of personalizing cancer treatment | Inactive | 13-Jul-2023 | ||
| CA-2887171-A1 | System and method for roadway pavement restoration | Inactive | 07-Apr-2014 | E01C23/06 |
Processa Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Processa Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Processa Pharmaceuticals Investments & Acquisitions (3)
Processa Pharmaceuticals’s most recent deal was a Merger/Acquisition with Vidya Therapeutics for . The deal was made on 29-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vidya Therapeutics | 29-Jul-2026 | Merger/Acquisition | Drug Discovery | ||
| Elion Oncology (PCS6422 License in Hanover, Maryland) | 30-Oct-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Heatwurx | 04-Oct-2017 | Merger/Acquisition | Machinery (B2B) |
Processa Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Processa Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vidya Therapeutics | Encinitas, CA | 2024 |
Processa Pharmaceuticals FAQs
-
When was Processa Pharmaceuticals founded?
Processa Pharmaceuticals was founded in 2017.
-
Where is Processa Pharmaceuticals headquartered?
Processa Pharmaceuticals is headquartered in Vero Beach, FL.
-
What is the size of Processa Pharmaceuticals?
Processa Pharmaceuticals has 12 total employees.
-
What industry is Processa Pharmaceuticals in?
Processa Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Processa Pharmaceuticals a private or public company?
Processa Pharmaceuticals is a Public company.
-
What is Processa Pharmaceuticals’s stock symbol?
The ticker symbol for Processa Pharmaceuticals is PCSA.
-
What is the current stock price of Processa Pharmaceuticals?
As of 13-Nov-2026 the stock price of Processa Pharmaceuticals is $1.82.
-
What is the current market cap of Processa Pharmaceuticals?
The current market capitalization of Processa Pharmaceuticals is $5.2M.
-
Who are Processa Pharmaceuticals’s competitors?
Vanda Pharmaceuticals, Novartis, Novavax, Damora Therapeutics ( Drug Discovery), and Gilead are some of the 52 competitors of Processa Pharmaceuticals.
-
What is Processa Pharmaceuticals’s annual earnings per share (EPS)?
Processa Pharmaceuticals’s EPS for 12 months was -$4.33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
